Stock Events

Stock Events

Mabion. 

zł0
1
+zł0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

4NovExpected
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-9.18%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
138.04MRevenue
-12.67MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0QGW.LSE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap26.03B
Biogen is a biotechnology company that develops and markets therapies for neurological and neurodegenerative diseases, competing in the biopharmaceutical sector similar to Mabion.
AMGEN
AMGN
Mkt Cap191.53B
Amgen is a global biotechnology firm that develops innovative human therapeutics, including in the oncology and inflammation sectors, directly competing with Mabion's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap170.84B
Gilead Sciences is a biopharmaceutical company that researches, develops, and commercializes drugs in areas similar to Mabion, particularly in the fields of oncology and viral diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.35B
Regeneron Pharmaceuticals is known for its innovative biopharmaceuticals in areas like oncology, competing directly with Mabion in the development of monoclonal antibodies.
Novartis
NVS
Mkt Cap293.34B
Novartis is a global healthcare company that operates in various therapeutic areas, including those targeted by Mabion, making it a direct competitor in the biopharmaceutical market.
Merck
MRK
Mkt Cap294.39B
Merck is a global healthcare company that produces medicines, vaccines, biologic therapies, and animal health products, competing in similar therapeutic areas as Mabion.
Pfizer
PFE
Mkt Cap156.77B
Pfizer is involved in the discovery, development, and manufacture of healthcare products including medicines and vaccines, directly competing with Mabion in various therapeutic areas.
Roche
RHHBY
Mkt Cap330.22B
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses worldwide, with a strong focus on oncology and immunology, overlapping with Mabion's focus areas.
Astrazeneca
AZN
Mkt Cap317.5B
AstraZeneca operates in segments that include oncology, cardiovascular, renal, metabolism, and respiratory, competing with Mabion in the biopharmaceutical and oncology sectors.
Johnson & Johnson
JNJ
Mkt Cap564.35B
Johnson & Johnson is a comprehensive healthcare firm that produces pharmaceuticals across a broad range of therapeutic areas, including those targeted by Mabion, making it a significant competitor.

About

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.
Show more...
CEO
ISIN
PLMBION00016

Listings

STU
DE
272.STU
MU
DE
272.MU
WA
PL
MAB.WA
LSE
GB
0QGW.LSE

0 Comments

Share your thoughts

FAQ

What is Mabion. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Mabion. stocks are traded under the ticker 0QGW.LSE.
What is Mabion. revenue for the last year?▼
Mabion. revenue for the last year amounts to 138.04M PLN.
What is Mabion. net income for the last year?▼
0QGW.LSE net income for the last year is -12.67M PLN.
In which sector is Mabion. located?▼
Mabion. operates in the Other sector.
When did Mabion. complete a stock split?▼
Mabion. has not had any recent stock splits.